GlassScriptPhysician profile
Cynthia D Heyne
NPI 1831588185
$2,430.96
in general payments reported to CMS, 2019-2025
27 companies · $807 in 2025
The $807 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $243 · 2023: $374 · 2024: $387 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $248.05 | 2025 | Fanapt |
| Abbvie INC. | $216.56 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $206.61 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $181.83 | 2022-2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $159.84 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $126.06 | 2021 | |
| Novo Nordisk INC | $125.00 | 2025 | |
| Amgen INC. | $120.00 | 2024 | Evenity |
| Neurocrine Biosciences, INC. | $116.40 | 2021-2025 | Ingrezza |
| Foundation Fusion Solutions, LLC | $115.81 | 2024 | |
| Cvrx, INC. | $106.09 | 2025 | Barostim Neo System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.04 | 2021 | |
| Medtronic, INC. | $74.28 | 2023 | Venaseal |
| Stimwave Technologies Incorporated | $58.85 | 2021 | |
| Kci USA, INC. | $58.78 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $53.12 | 2024-2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $52.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.59 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $45.83 | 2023 | Gemtesa |
| Lilly USA, LLC | $44.95 | 2021-2025 | Kisunla, Amyvid |
| Ucb, INC. | $44.05 | 2024-2025 | Briviact |
| Neurelis, INC. | $30.45 | 2022-2023 | Valtoco |
| Sk Life Science, INC. | $26.10 | 2023 | |
| Indivior INC. | $19.32 | 2023 | Perseris |
| Sun Pharmaceutical Industries INC. | $18.22 | 2021 | |
| Acadia Pharmaceuticals INC | $17.09 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Heyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.